Protein kinase inhibitors

A compound of formula II:

• and/or a salt, an enantiomer or an enantiomeric mixture thereof:
• wherein W1, W2, and W3 are independently hydrogen or deuterium;
• wherein Y is C—H or nitrogen;
• wherein R2, R3, and R4 are independently hydrogen;
• halogen;
• alkoxyl;
• lower alkyl or lower alkenyl, wherein the lower alkyl or lower alkenyl is optionally substituted with one or more substituents selected from —OH and alkoxyl, wherein alkoxyl is methoxy, ethoxy, propyloxy, or tert-butoxy;
• or optionally substituted heterocyclo, wherein optionally substituted includes [—NR7R6], wherein R6 and R7 are independently hydrogen, lower alkyl, or lower alkenyl;
• and
• wherein X is independently hydrogen, —(CH2)n—OR5, or [—NR7R6], wherein n is an integer number from 0 to 4 and R5 R6 are independently hydrogen, lower alkyl, or lower alkenyl.

A compound of formula III:

• and/or a salt, an enantiomer or an enantiomeric mixture thereof:
• wherein W1, W2, and W3 are independently hydrogen or deuterium;
• wherein Y is C—H or nitrogen;
• wherein R2, R3, and R4 are independently H;
• halogen;
• alkoxyl;
• lower alkyl or lower alkenyl, wherein the lower alkyl or lower alkenyl is optionally substituted with one or more substituents selected from —OH and alkoxyl, wherein alkoxyl is methoxy, ethoxy, propyloxy, or tert-butoxy;
• or optionally substituted heterocyclo, wherein optionally substituted includes [NR7R6], wherein R6 are independently hydrogen, lower alkyl, or lower alkenyl.

A pharmaceutical composition comprising a compound of formula 1

• and/or a salt, an enantiomer or an enantiomeric mixture thereof;
• wherein
• W1, W2, and W3 are independently hydrogen or deuterium;
• Y is C—H or nitrogen;
• R1 is
• -Q-A
• wherein
• Q is a single bond directly attaching A to a ring carbon atom, or a methylene or ethylene group connecting A to a ring carbon atom;
• and
• A is
• wherein
• Y1 is C—H or nitrogen and Y2 is carbon and wherein A is a five or six membered ring;
• Z1 and Z2 are independently hydrogen, —(CH2)n—OR5, or [—NR7R6], where n is an integer number from 0 to 4, and R5 R6 are independently hydrogen, lower alkyl, or lower alkenyl;
• T1 and T2 are independently an integer number from 0 to 4 with the provisos that when T1 or T2 is 0, —(CH2)T1 or —(CH2)T2 is a single bond;
• R2 and R3 are independently hydrogen;
• halogen;
• alkoxyl;
• lower alkyl or lower alkenyl, wherein the lower alkyl or lower alkenyl is optionally substituted with one or more substituents selected from —OH and alkoxyl, wherein alkoxyl is methoxy, ethoxy, propyloxy, or tert-butoxy;
• or optionally substituted heterocyclo, wherein optionally substituted includes [—NR7R6], wherein R6 and R7 are independently hydrogen, lower alkyl, or lower alkenyl;
• and wherein the positions of R1, R2 and R3 are exchangeable;
• and a pharmaceutically acceptable excipient or carrier.